Patent Cliff Dashboard
A patent cliff occurs when a blockbuster drug loses its patent or regulatory exclusivity protection, allowing generic manufacturers (for small molecules) or biosimilar developers (for biologics) to enter the market with cheaper alternatives. Revenue for the originator drug typically falls 60–90% within two to three years — a sudden drop that pharma companies and investors call "going over the cliff."
Drug patents in the United States last 20 years from the filing date, but by the time a drug reaches approval, the effective commercial life is often 10–12 years. On top of patents, the FDA grants separate market exclusivity periods (5 years for new chemical entities, 12 years for biologics) which independently block generic or biosimilar competition. A drug is fully exposed only after both the last patent and the last exclusivity period expire.
The Pro version of this dashboard tracks 122 blockbuster drugs across 18 major pharmaceutical companies using actual company-reported revenue from SEC 10-K/10-Q filings, with patent and exclusivity expiry dates from the FDA Orange Book, FDA Purple Book, and manually curated biologic data — grouped by expiry year with interactive revenue charts for each drug.
US vs. International Patent Cliffs
Patents are country-specific
A patent granted by the USPTO only protects a drug in the United States. Separate applications must be filed in each jurisdiction — typically via the European Patent Office (EPO) for the EU, plus Japan, China, and other markets individually. Patents in each region can have different filing dates, term lengths, and litigation outcomes, so the US cliff and the EU cliff for the same drug can differ by years.
Exclusivity periods also differ
The US grants 12 years of biologic exclusivity (BPCIA) and 5 years for new small molecules (Hatch-Waxman). The EU grants 8+2 years of data and market exclusivity, with an optional +1 year for new indications. Japan and other markets have their own rules. In practice, EU biosimilars often launch 3–5 years before their US counterparts, meaning international revenue declines first while US revenue remains protected.
Humira example: EU compound patents expired in October 2018 — biosimilars launched in Europe immediately. US patents held until January 2023 due to a stronger patent estate and litigation settlements. AbbVie's international Humira revenue was already declining sharply by 2019 while US revenue stayed near peak until 2023. This is why companies report US and international revenue separately — the cliffs land at different times.
The Canonical Example: Humira (adalimumab)
World's best-selling drug for a decade — then biosimilars arrived
2022 → 2025
AbbVie's Humira (adalimumab) was the world's top-selling drug from 2012–2022, generating nearly $20B annually at its peak. When US compound patents expired in January 2023, over 10 biosimilar versions launched within months. Revenue fell from $19.7B in 2022 to $14.0B in 2023, $9.1B in 2024, and an estimated $5.3B in 2025 — a 73% drop in three years. The chart below (Pro) shows the full quarterly trajectory. AbbVie had anticipated the cliff and shifted investment to Skyrizi and Rinvoq, which are now growing rapidly.
Unlock the full Patent Cliff Dashboard
Track every blockbuster drug losing patent protection through 2030 — with actual SEC-reported revenue, company exposure rankings, and historical trajectories.
Company Exposure Ranking
Share of each company's tracked drug revenue losing patent protection by 2030. Higher = more revenue concentrated in soon-to-expire drugs.
Based on annualized revenue from tracked drugs in our SEC filings dataset — not total company revenue. Companies with highly concentrated cliff exposure face the steepest revenue defense challenges.
Cliff Timeline 2026–2030
Each bubble = one drug. Size = annualized revenue. Click a bubble to jump to the drug.
Upcoming Cliffs 2026–2030
265 blockbuster drugs tracked by actual SEC-reported revenue. 205 have patent/exclusivity dates.
2026 (This year)
Abatacept biosimilars (Samsung Bioepis SB17, Pfizer's PF-06438179) are in Phase 3. Orencia is not a strategic priority for BMS — Eliquis and Opdivo dominate. Expect 50–70% revenue decline by 2028 as RA market shifts toward IL-17/IL-23 inhibitors and biosimilars.
BPCIA floor estimate (approval Sep 2014 + 12 years). Trulicity is a GLP-1 Fc-fusion biologic — biosimilar development is harder than for a typical mAb. But the real cliff is competitive, not legal: Mounjaro, Ozempic, and Zepbound have been eroding Trulicity share for two years ahead of any biosimilar entry. Lilly's own next-gen GLP-1s are cannibalizing it. The 2026 BPCIA date is a floor — Lilly has indicated patent protection extends further, but the commercial cliff is already in motion.
Sugammadex generics have been filed — multiple ANDAs pending since 2022 after key patents challenged. Merck has not invested heavily in defending this anesthesia recovery asset. Generic entry could be rapid and near-total given the small molecule structure.
Already declining — tofacitinib generics entered Oct 2022 via settlement. Patent cliff has effectively already happened. Label restrictions (JAK class cardiovascular/cancer warning, 2021) further accelerated the switch to Rinvoq and Skyrizi. This is a cliff in the rearview mirror.
2027
IL-17A biosimilars are in Phase 3 development. The IL-17/IL-23 class is crowded — Cosentyx, Tremfya, Skyrizi all compete. Biosimilar entry adds a fourth price pressure vector. Lilly's revenue impact may be partially cushioned by Mounjaro/Zepbound growth, but Taltz alone is ~$2.5B at risk.
BPCIA floor estimate (approval Aug 2015 + 12 years). Amgen's PCSK9 inhibitor faces biosimilar development from Samsung Bioepis and Celltrion, though no biosimilar is FDA-approved yet. Unlike immunology mAbs, the PCSK9 market is still expanding rapidly — biosimilar impact may be partially cushioned by overall category growth as cardiovascular prescribing shifts toward aggressive LDL lowering.
Natalizumab biosimilars from Sandoz (Tyruko — FDA-approved 2023, launched 2024) are already on market. Revenue is declining ahead of the 2027 patent date. Biogen has shifted MS investment to Leqembi (Alzheimer's) and Skyclarys, reducing reliance on Tysabri.
2028
The defining patent cliff of the decade. Pembrolizumab is the world's top-selling drug at ~$25B/yr. US compound patent expires Dec 2028; biosimilars from Samsung Bioepis, Organon, Sandoz, and others are in Phase 3. Merck is racing to file combination patents and pivoting to subcutaneous Keytruda (MK-3475A) — but a 70–80% revenue loss is widely expected by 2031.
EU patent already expired Dec 2026 — European revenue is declining now. US cliff follows Dec 2028. BMS has invested in Opdualag (nivolumab + relatlimab), CD19/20 combinations, and next-gen I/O assets. The question is whether newer combinations extend commercial life before the cliff fully lands.
2029
Daratumumab's key US patent expires May 2029. Despite J&J's strong patent filing strategy, biosimilars from Celltrion, Samsung, and Pfizer are in development. Darzalex Faspro (subcutaneous formulation) has a separate patent that may extend protection — J&J's strategy mirrors AbbVie's Humira defense playbook.
Ocrelizumab patents expire March 2029 (US). Celltrion's CT-P53 is in Phase 3. Roche has responded by developing fenebrutinib and tolebrutinib (BTK inhibitors) as next-gen MS assets. The biosimilar transition may be slower than mAb precedents due to complex manufacturing.
Secukinumab US patent expires Jan 2029. Biosimilars in development. IL-17A class is highly competitive — Taltz, Tremfya, Skyrizi all compete, and Skyrizi biosimilars will lag behind. Novartis may see earlier revenue erosion from competing originator drugs before biosimilars even enter.
US patents extend to April 2029 — substantially longer than the EU (expired 2015), where biosimilars already eroded Amgen's European revenue significantly. When US biosimilars enter, expect rapid erosion: the US biosimilar market is now well-established. Amgen anticipates this and is investing in Tezspire and Otezla to offset.
BPCIA floor estimate (approval Nov 2017 + 12 years). AstraZeneca's IL-5R mAb for severe eosinophilic asthma. The severe asthma biologic market is fragmented across Nucala (GSK), Dupixent (Regeneron/Sanofi), and Tezspire (AZ/Amgen itself) — biosimilar development economics are weaker in a crowded class than in TNF space. Expect slow post-cliff erosion rather than a Humira-style collapse.
BPCIA floor estimate (approval Oct 2017 + 12 years). Gilead/Kite's CD19 CAR-T was the first commercial CAR-T. CAR-T biosimilars essentially don't exist as a category — these are personalized autologous cell therapies manufactured patient-by-patient, with no FDA biosimilar pathway. The 'cliff' is academic unless off-the-shelf allogeneic CAR-Ts (Allogene, Caribou) succeed commercially. Real competition comes from newer CAR-Ts (Breyanzi, Carvykti) and bispecifics (Tecvayli, Talvey).
BPCIA floor estimate (approval May 2017 + 12 years). Sanofi/Regeneron's IL-6R mAb for rheumatoid arthritis. Commercial priority is low — the much larger Actemra (Roche tocilizumab) dominates the IL-6 class, and biosimilar developers have prioritized Actemra over Kevzara. Cliff impact likely modest because revenue base is already small.
2030
Nusinersen SMA therapy patents expire Dec 2030. The SMA market has transformed — Zolgensma (gene therapy, one-time cure) and Evrysdi (oral risdiplam) have captured most new patients since 2020. Spinraza revenue has already been declining due to competitive modality displacement, not just patent expiry.
BPCIA floor estimate (approval Sep 2018 + 12 years). Lilly's CGRP mAb for migraine prevention. The CGRP class is fragmented (Aimovig, Ajovy, Vyepti all compete), and oral CGRP antagonists (Nurtec, Qulipta) are eating into the injectable market. Biosimilar economics look weak in a crowded, pressured class — the commercial cliff may land earlier than the patent cliff.
Historical Patent Cliffs — Reference Trajectories
Drugs that have already crossed their cliff — actual revenue arcs from peak to post-generic/biosimilar entry. Use these as reference points for what the upcoming cliffs above are likely to resemble.
Biosimilars (Jubbonti, Wyost, Bkemv) were approved in 2023–2024 but launched only in mid-2025. Revenue hasn't declined yet — biosimilar uptake typically lags launch by 6–12 months. Decline is expected to accelerate through 2026.
Omalizumab biosimilars (Zenvia, Omlyclo) just launched in 2025. Revenue still at peak — very early stage of competition. Unlike small molecules, biologic patients often remain on the originator drug due to formulary inertia and physician preference.
Omalizumab biosimilars (Zenvia, Omlyclo) just launched in 2025. Revenue still at peak — very early stage of competition. Unlike small molecules, biologic patients often remain on the originator drug due to formulary inertia and physician preference.
Slower decline than Humira because fewer biosimilars entered (2–3 vs 10+), and ustekinumab's complex MOA (IL-12/23) leads to stronger physician inertia. Biosimilar uptake in Crohn's disease is particularly slow.
10+ biosimilars launched day one in Jan 2023 after AbbVie's patent estate expired. AbbVie had anticipated the cliff and invested heavily in Skyrizi and Rinvoq — combined they now exceed Humira's peak revenue.
Sitagliptin generics entered Oct 2023 via settlement. Revenue decline compounded by GLP-1 competitive pressure — Ozempic and Mounjaro have largely displaced older DPP-4 inhibitors in new prescriptions.
Sitagliptin generics entered Oct 2023 via settlement. Revenue decline compounded by GLP-1 competitive pressure — Ozempic and Mounjaro have largely displaced older DPP-4 inhibitors in new prescriptions.
Generic teriflunomide entered in Sep 2023 after patent settlements. Revenue collapse accelerated in 2024 — Sanofi had already shifted MS investment to Kesimpta partnership with Novartis.
Fastest collapse in this dataset — multiple generic manufacturers entered simultaneously on the first day of the Mar 2022 settlement window. Small molecules face aggressive price competition with near-immediate erosion, unlike biologics.
PTAB (Patent Trial and Appeal Board) invalidated Biogen's key fumarate ester patent in Aug 2020 after a successful IPR challenge. Generics launched immediately. A warning sign that patent estates can be challenged even mid-lifecycle.
Slowest decline in this dataset. Insulin biosimilars face unique barriers: pharmacy substitution restrictions, device interchangeability requirements, and patient resistance to switching. Sanofi's Toujeo (next-gen glargine) captured upgrading patients.
60 drugs with no active cliff — vaccines, off-patent originators, orphan/rare disease, cell therapies
These drugs are tracked by SEC-reported revenue but have no meaningful upcoming cliff event. Reasons: vaccines (e.g. Comirnaty, Beyfortus), already off-patent originators (Symbicort, Avonex, Zoladex, Aranesp), orphan/rare disease enzymes (Naglazyme, Aldurazyme, Brineura, Palynziq), or cell therapies where the biosimilar pathway doesn't yet exist. A small number are unmatched brand-name variants we haven't linked to our drug database yet.
Data Sources & Methodology
For Medicare Part D spending analysis (public payer view), see the Medicare Part D Analysis.